Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma

JAMA Oncology - United States
doi 10.1001/jamaoncol.2016.3160
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Medical Association (AMA)

Related search

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment

Current Hematologic Malignancy Reports
Cancer ResearchOncologyHematology
2016English

Minimal Residual Disease Testing After Stem Cell Transplantation for Multiple Myeloma

Bone Marrow Transplantation
TransplantationHematology
2015English

Ficolled Bone Marrow Is Superior to Bone Marrow Buffy Coat for Detection of Minimal Residual Disease in Multiple Myeloma

Hematology
Hematology
2019English

Residual Serum Monoclonal Protein Predicts Progression-Free Survival in Patients With Previously Untreated Multiple Myeloma

Cancer
Cancer ResearchOncology
2010English

Flow Cytometry in the Diagnosis and Monitoring of Minimal Residual Disease in Multiple Myeloma

Oncogematologiya
OncologyHematology
2017English

Serological Normalisation as a Surrogate Marker for Minimal Residual Disease Negativity in Multiple Myeloma

British Journal of Haematology
Hematology
2018English

Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?

Clinical Cancer Research
Cancer ResearchOncology
2015English

Immunoglobulin Heavy/Light Chain Ratios Improve Paraprotein Detection and Monitoring, Identify Residual Disease and Correlate With Survival in Multiple Myeloma Patients

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2013English

Minimal Residual Disease Assessment in Multiple Myeloma: Utility and Feasibility in Resource Constraint Settings of India

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy